Wexler Boley & Elgersma LLP, Miller Law LLC, Hilliard Shadowen LLP, Motley Rice LLC, and Spector Roseman & Kodroff P.C. Announce a $30 Million Class Action Settlement for Those Who May Have Purchased or Provided Reimbursement for the Drug Suboxone or Gene
Retrieved on:
Monday, August 28, 2023
AK, AB, ME, Vexatious litigation, Payment card interchange fee and merchant discount antitrust litigation, CO, District court, Notice, Court, Hearing, RI, OR, Market Street, PR, Dubrovka, Dubrovsky Settlement Administrative Okrug, Dubrovsky District, Bryansk Oblast, Buprenorphine, Clerk, FORM, Letter, Reckitt, Lawsuit, Fairness, HI, Settlement, Court order, OK, Summons, Insurance, Buprenorphine/naloxone, Class, MD, Indivior
The Court has preliminarily approved a proposed settlement between the Class and Indivior (the "Settlement").
Key Points:
- The Court has preliminarily approved a proposed settlement between the Class and Indivior (the "Settlement").
- The proposed Settlement will provide for the payment of $30 million (the "Settlement Fund") to resolve the Class claims against Indivior.
- The deadlines contained in this Notice may be amended by Court Order, so check the Settlement website for any updates.
- SOURCE Wexler Boley & Elgersma LLP, Miller Law LLC, Hilliard Shadowen LLP, Motley Rice LLC, and Spector Roseman & Kodroff P.C.